Clinical trials: Epithelial Mesothelioma
Solid Tumor, Lymphoma
Study of Oral PXD101 in Patients With Advanced Solid Tumors or Lymphoma
This is a Phase I dose escalation study of PXD101 administered orally. Oral belinostat will be given once or twice daily at various dosing schedules to patients with solid tumors.
- Trial name
- NCT00413075
- Testing
- oral belinostat
- Where
- 6 sites in United States, Denmark and 1 more
- Volunteers
- 121 people
- Sponsor
- Valerio Therapeutics
Malignant Mesothelioma
Liposomal-Cisplatin Analogue (L-NDDP) in Treating Patients With Malignant Pleural Mesothelioma
RATIONALE: Patient abstract not available PURPOSE: Patient abstract not available
- Trial name
- NCT00004033
- Testing
- liposomal NDDP, therapeutic thoracoscopy
- Where
- 2 sites in United States
- Volunteers
- 30 people
- Sponsor
- NYU Langone Health
Advanced Cancer, Metastatic Cancer
A Study of LY3023414 in Participants With Advanced Cancer
The purpose of this study is to find a recommended dose level and schedule of dosing LY3023414 that can safely be taken by participants with advanced or metastatic cancer.
- Conditions
- Advanced Cancer, Metastatic Cancer, Non-Hodgkin's Lymphoma, Metastatic Breast Cancer
- Trial name
- NCT01655225
- Testing
- LY3023414, Midazolam, Fulvestrant
- Where
- 8 sites in United States, Italy and 1 more
- Volunteers
- 156 people
- Sponsor
- Eli Lilly and Company
Thyroid Cancer, Renal Cell Carcinoma
Study of Nanrilkefusp Alfa Alone and With Pembrolizumab in Adult Patients With Advanced/Metastatic Solid Tumors
A multicenter open-label phase 1/1b study to evaluate the safety and preliminary efficacy of nanrilkefusp alfa as monotherapy and in combination with pembrolizumab in patients with selected advanced/metastatic solid tumors
- Conditions
- Thyroid Cancer, Renal Cell Carcinoma, Non Small Cell Lung Cancer, Small-cell Lung Cancer
- Trial name
- NCT04234113
- Testing
- Nanrilkefusp alfa, Pembrolizumab
- Where
- 12 sites in United States, Czechia and 2 more
- Volunteers
- 115 people
- Sponsor
- SOTIO Biotech AG
Mesothelioma
An Open-label, Phase II Trial of ZD1839 (IRESSA) in Patients With Malignant Mesothelioma
This study is a multicentre, open label, non-comparative, two stage phase II trial to assess the activity of ZD1839 (IRESSA) in patients with malignant mesothelioma.
- Trial name
- NCT00787410
- Testing
- ZD1839
- Volunteers
- 23 people
- Sponsor
- AstraZeneca
Malignant Pleural Mesothelioma
A Phase I/II Study of First Line Vorinostat With Pemetrexed-cisplatin, in Patients With Malignant Pleural Mesothelioma
Mesothelioma is a relatively rare cancer which is becoming more common. It can affect one of two areas; the pleura (the lining of the lung) or the peritoneum (the lining of the abdomen).
- Trial name
- MESO-02 (NCT01353482)
- Testing
- Cisplatin, Pemetrexed, Vorinostat
- Sponsor
- University College, London
Malignant Pleural Disease, Mesothelioma
Malignant Pleural Disease Treated With Autologous T Cells Genetically Engineered to Target the Cancer-Cell Surface Antigen Mesothelin
The purpose of this Phase I study is to test the safety of different doses of specially prepared immune cells (called "T cells") collected from blood.
- Conditions
- Malignant Pleural Disease, Mesothelioma, Metastases, Lung Cancer
- Trial name
- NCT02414269
- Testing
- iCasp9M28z T cell infusions, cyclophosphamide, pembrolizumab
- Where
- 6 sites in United States
- Volunteers
- 113 people
- Sponsor
- Memorial Sloan Kettering Cancer Center
Mesothelioma, BAP1 Loss of Function
Study of the EZH2 Inhibitor Tazemetostat in Malignant Mesothelioma
This is a Phase 2, multicenter, open-label, 2-part, single-arm, 2-stage study of tazemetostat 800 mg two times a day (BID) administered orally.
- Trial name
- NCT02860286
- Testing
- Tazemetostat
- Where
- 16 sites in United States, France and 1 more
- Volunteers
- 74 people
- Sponsor
- Epizyme, Inc.
Mesothelioma
A Phase 2 Study of Durvalumab in Combination With Tremelimumab in Malignant Pleural Mesothelioma
This research study is studying a pair of immunotherapies as a possible treatment for malignant pleural mesothelioma. The drugs involved in this study are: Durvalumab Tremelimumab
- Trial name
- NCT03075527
- Testing
- Tremelimumab, Durvalumab
- Where
- United States
- Volunteers
- 19 people
- Sponsor
- Dana-Farber Cancer Institute
Malignant Mesothelioma
Antineoplaston Therapy in Treating Patients With Advanced Mesothelioma
Current therapies for advanced Mesothelioma provide limited benefit to the patient. The anti-cancer properties of Antineoplaston therapy suggest that it may prove beneficial in the treatment of advanced Mesothelioma.
- Trial name
- NCT00003508
- Testing
- Antineoplaston therapy (Atengenal + Astugenal)
- Where
- United States
- Volunteers
- 8 people
- Sponsor
- Burzynski Research Institute
Mesothelioma, Mesothelioma Malignant
A Pilot Study to Explore the Role of Gut Flora in Metastatic Mesothelioma
This study seeks to correlate microbiome sequencing data with information provided by patients and their medical records.
- Conditions
- Mesothelioma, Mesothelioma Malignant, Mesothelioma; Lung, Mesotheliomas Pleural
- Trial name
- NCT04214015
- Testing
- No intervention
- Where
- United States
- Sponsor
- ProgenaBiome
Mesothelioma
Anti-Mesothelin Immunotoxin LMB-100 Followed by Pembrolizumab in Malignant Mesothelioma
Background: Treatment outcomes for people with pleural or peritoneal mesothelioma are often poor. The drug LMB-100 can attack and kill cancer cells. The drug pembrolizumab helps the immune system fight cancer.
- Trial name
- NCT03644550
- Testing
- LMB-100, Pembrolizumab
- Where
- United States
- Volunteers
- 18 people
- Sponsor
- National Cancer Institute (NCI)
MALIGNANT PLEURAL MESOTHELIOMA
Molecular Predictors of Pemetrexed and Carboplatin Response in Malignant Pleural Mesothelioma (MPM) Patients
The aim of the present study is to investigate the molecular predictors of pemetrexed and carboplatin response in tumor samples of a series of MPM patients extracting the DNA and genotyping for the TSER polymorphism.
- Trial name
- NCT00867711
- Where
- Italy
- Volunteers
- 121 people
- Sponsor
- Istituto Clinico Humanitas
Acute Leukemia, Multiple Myeloma
INTEGRATIVE "MULTI-OMICS" AND FUNCTIONAL PLATFORM FOR THE COMPLETE DIAGNOSTIC CHARACTERIZATION OF TUMORS: THE ITALIAN TUMOR CHEMOGENOMIC PROFILER (IT-TCP)
This is a multicenter, experimental preclinical study conducted on primary samples from patients diagnosed with hematological or solid neoplasms defined as high risk.
- Conditions
- Acute Leukemia, Multiple Myeloma, Squamous Cell Carcinoma, Pleural Mesothelioma
- Trial name
- IT-TCP POS (NCT07403630)
- Testing
- Functional tests, Multi-omics analyses, Cytogenetics/ FISH
- Where
- 2 sites in Italy
- Volunteers
- 300 people
- Sponsor
- Azienda Ospedaliero-Universitaria di Parma
Mesothelioma, Solitary Fibrous Tumor of the Pleura
Chemotherapy Followed by Surgery and Neoadjuvant Hemothoracic Intensity Modified Radiation Therapy (IMRT) for Patients With Malignant Pleural Mesothelioma
The purpose of this study is to determine the response rate and overall survival in patients that have been diagnosed with mesothelioma and will undergo chemotherapy, surgery and intensity modified radiation therapy (IMRT) as…
- Trial name
- NCT02613312
- Where
- United States
- Volunteers
- 8 people
- Sponsor
- Mayo Clinic
Advanced Malignant Mesothelioma, Extensive Stage Small Cell Lung Cancer
Cryotherapy in Treating Patients With Lung Cancer That Has Spread to the Other Lung or Parts of the Body
This pilot clinical trial studies the side effects of cryotherapy (cryoablation [CA]) in treating patients with lung cancer. Cryotherapy kills cancer cells by freezing them.
- Conditions
- Advanced Malignant Mesothelioma, Extensive Stage Small Cell Lung Cancer, Lung Metastases, Recurrent Malignant Mesothelioma
- Trial name
- NCT01325753
- Testing
- cryotherapy, quality-of-life assessment
- Sponsor
- Wake Forest University Health Sciences
Malignant Pleural Mesothelioma, Advanced
Oncolytic Adenovirus(H101) Combined With PD-1 Inhibitors in Patients With Advanced Malignant Pleural Mesothelioma
The purpose of this study is to evaluate the efficacy and safety of Oncolytic Adenovirus(H101) combined with PD-1 inhibitor in patients with advanced malignant pleural mesothelioma who have previously been resistant to advanced…
- Trial name
- NCT06031636
- Testing
- Oncolytic Adenovirus H101, Programmed death receptor-1 inhibitor
- Where
- China
- Volunteers
- 15 people
- Sponsor
- Tianjin Medical University Second Hospital
Lymphoma, Mesothelioma
Influence of Psychosocial Distress and Lifetime Trauma Exposure on Traumatic Stress Among Oncology Patients on Clinical Trials
Background: A cancer diagnosis is a threat to life and bodily integrity. This can cause people with cancer to experience traumatic stress.
- Conditions
- Lymphoma, Mesothelioma, Prostate Cancer, Leukemia
- Trial name
- NCT02948413
- Where
- United States
- Volunteers
- 55 people
- Sponsor
- National Institutes of Health Clinical Center (CC)
Solid Tumor Malignancies, Malignant Mesothelioma (MM)
Study of TYK-01054 Capsules in Patients With Advanced Solid Tumors
This study is to evaluate the safety, tolerability, pharmacokinetics, and antitumor activity of the TEAD inhibitor TYK-01054 capsules in patients with locally advanced or metastatic advanced solid tumors
- Trial name
- NCT07282873
- Testing
- TYK-01054
- Where
- China
- Volunteers
- 219 people
- Sponsor
- TYK Medicines, Inc
Uveal Melanoma, Cutaneous Melanoma
Frequency and Clinical Phenotype of BAP1 Hereditary Predisposition Syndrome
This research will have a significant impact on the overall management of those cancer patients and their family members who are at risk for hereditary cancer due to germline inactivation of BAP1.
- Conditions
- Uveal Melanoma, Cutaneous Melanoma, BAP1 Gene Mutation, Renal Cell Carcinoma
- Trial name
- NCT04792463
- Where
- United States
- Volunteers
- 500 people, healthy volunteers welcome
- Sponsor
- Mohamed Abdel-Rahman